{
  "id": 5359185,
  "title": "GSK wagers up to $1.3B on a different kind of cancer drug",
  "url": "https://urgent.news/2026/09/03/gsk-wagers-up-to-1-3b-on-a-different-kind-of-cancer-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T16:01:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/gsk-hutchmed-egfr-kras-cancer-drug-deal-china/829542/"
  },
  "original_language": "en",
  "account": null,
  "summary": "With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}